Healthy_back (healthy_back) wrote,

Эра антибиотиков подходит к концу
Knowing when to stop antibiotic therapy

Gwendolyn L Gilbert

Empirical antibiotic therapy that turns out to be unnecessary, on review, can (and should) be stopped immediately

After 50 years of widespread antibiotic use, we have reached the point where experts are seriously predicting “a postantibiotic era” and the World Health Organization has declared antibiotic resistance “a threat to global security”.1 No one can doubt the enormous benefits of antibiotics in curing or preventing serious sequelae of infections that were once the main causes of death and chronic illness, and enabling modern medical therapies that involve significant immune suppression.

These benefits are dramatic, and toxic side effects are apparently few. This makes it tempting — even now, when we know the risks — to prescribe antibiotics empirically at the first hint of infection, even viral infection,2 lest it progress to serious sepsis (and potential medicolegal or professional embarrassment3). Although unnecessary antibiotic use is sometimes driven by patients' expectations, they can be modified by public education.4

During the first 30 years of the antibiotic era, the release of each new antibiotic was almost always followed by the emergence of resistance in some previously susceptible bacteria, but there were always new antibiotics in the pipeline, until recently. Now the pipeline has dried up and the incidence and spectrum of resistance among most common pathogens have reached alarming levels.1 How have we come to this point, and what can we do to avoid the “end of the antibiotic era”?

How can we improve our use of antibiotics?

We still argue about how to optimise antibiotic use, but there are some (more or less) undisputed facts:

the incidence of antibiotic resistance is, broadly, proportional to the total amount of antibiotics used,5 notwithstanding many confounding variables;
individual antibiotic exposure rapidly alters normal gut microflora, which can take months to recover, risking overgrowth or acquisition of (and, potentially, infection with) multiresistant bacteria, Clostridium difficile or yeasts and spread to hospital, household or nursing home contacts6 — and the broader the spectrum and the longer the course, the greater the risk; infections with antibiotic-resistant bacteria are more difficult to treat and are associated with higher mortality — antimicrobial resistance is estimated to cost the United States health system US$21–34 billion per annum;1 and all antibiotics have some specific adverse side effects such as allergy (or, rarely, anaphylaxis) or dose-related haematological, gastrointestinal, renal or hepatic toxicity.

Surveys of antibiotic use in hospital and community settings show that a third to a half of all prescriptions are discordant with widely available antibiotic guidelines.7,8 Individual decisions to prescribe are often driven by the prescriber's experience, confidence and tolerance of risk, rather than by objective clinical indications.2 Antimicrobial stewardship programs are designed to support and share responsibility for logical, evidence-based antibiotic prescribing decisions in the context of inevitable clinical uncertainty, and they can reduce unnecessary — and overall — antibiotic use, without adverse patient outcomes.9,10

In seriously ill patients with suspected bacterial sepsis, initial empirical therapy often means high-dose, broad-spectrum “cover”, justified by evidence that the mortality increases rapidly with every hour's delay in starting effective therapy.11 For example, recommended empirical therapy for patients with neutropenia who develop fever is to give piperacillin–tazobactam or a fourth-generation cephalosporin.12 The need for immediate, effective therapy in severe sepsis is often extrapolated to milder (suspected) infections, with non-specific symptoms, for which therapy may not be necessary or could be delayed until test results are available to guide it.

Whether to treat and the appropriate choice of empirical therapy are not straightforward decisions, even with the help of prescribing guidelines. However, starting empirical therapy does not mean the patient is committed to a fixed treatment course. Too often, initial therapy is continued without review, even when diagnostic tests indicate an alternative diagnosis (non-infective condition or viral infection) for which no antibiotic is needed or a narrower spectrum agent would suffice. For example, Streptococcus pneumoniae isolated from a blood culture from a patient with severe community-acquired pneumonia is an indication to change from commonly prescribed empirical therapy — ceftriaxone plus azithromycin — to benzylpenicillin alone.12

Duration of treatment and resistance

There is a common misconception that resistance will emerge if a prescribed antibiotic course is not completed. Premature cessation of antibiotic therapy will not increase the risk that resistance will emerge. For most infections, the recommended duration of therapy (5–14 days, depending on syndrome) is based on expert opinion and convention, rather than solid evidence. However, for many syndromes associated with bacteraemia, there is no difference in outcome when shorter courses are used.13,14 In practice the optimal duration of therapy depends on clinical syndrome, the causative organism, whether source control is possible and the patient's response to therapy.14 For example, only 3–5 days of treatment is needed for meningococcal meningitis, compared with 10–14 days for pneumococcal meningitis.12 Additional studies are needed to validate shorter courses of antibiotic therapy for many other infections.

Resistance is much more likely to occur with long antibiotic courses, which are rarely indicated except when the site of infection is relatively inaccessible (in biofilm in sites such as a cardiac valve or foreign body or in an abscess); these infections often cannot be cured without surgical removal of the source or drainage of pus. There is no risk — and every advantage — in stopping a course of an antibiotic immediately a bacterial infection has been excluded or is unlikely; and minimal risk if signs and symptoms of a mild infection have resolved.

Commissioned; externally peer reviewed. (
Естественный человеческий антибиотик дермицидин, который выделяется вместе с потом, оказался эффективным против самых распространенных бактерий и грибков.
антибиотики, кожа, туберкулез, стафилококковые инфекции
Антибиотики, входящие в состав человеческого пота, защищают организм от проникновения инфекции при небольших порезах, царапинах или укусах насекомых. В большинстве своем такими антибиотиками являются вещества из группы антимикробных пептидов. Они более эффективны, чем традиционные антибиотики, так как у опасных микроорганизмов не так быстро развивается устойчивость (резистентность) к ним.

Международная группа ученых проанализировала молекулярную структуру дермицидина. Его молекула активируется при попадании в соленый пот с кислым рН. При этом дермицидин формирует в клеточных стенках бактерий сквозные каналы, которые остаются стабильными за счет молекул цинка, тоже присутствующих в составе пота. В результате внутрь вредных микроорганизмов начинают бесконтрольно поступать вода и заряженные ионы, что приводит к гибели бактерий.

Исследования показали, что дермицидин эффективно работает с самыми разными типами клеточных мембран. Это позволяет объяснить, почему он одинаково эффективен против туберкулезной палочки, стафилококковых бактерий и некоторых грибков. Обнаруженные свойства дермицидина дают надежду на использование его для борьбы с мультирезистентными штаммами золотистого стафилококка - микроорганизмами, который не поддаются лечению традиционными антибиотиками и приводят к развитию сепсиса и пневмонии.

Результаты исследования опубликованы в журнале Proceedings of the National Academy of Sciences.
Tags: Культура
  • Post a new comment


    default userpic

    Your reply will be screened

    Your IP address will be recorded 

    When you submit the form an invisible reCAPTCHA check will be performed.
    You must follow the Privacy Policy and Google Terms of use.